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ABSTRACT 
IDENTIFICATION OF RNA SPLICING ERRORS RESULTING IN HUMAN 
ORNITHINE TRANSCARBAMYLASE DEFICIENCY. Russ P. Carstens. 
Department of Human Genetics, Yale University School of Medicine. New 
Haven, Connecticut. 
Ornithine transcarbamylase (OTC) is an X-linked, liver specific enzyme 
which catalyzes the second step of the urea cycle. In humans, inherited 
deficiency of OTC in hemizygous affected males usually results in severe 
ammonia intoxication and early death. In order to characterize mutations 
responsible for OTC deficiency, we used the polymerase chain reaction to 
amplify cDNAs prepared from patient livers, obtained at autopsy, which 
demonstrated no OTC enzyme activity. Of eleven livers tested, it was possible 
to produce amplifiable cDNA from seven. In three of these seven cases, smaller 
than normal products were observed. Sequencing of the cDNAs revealed that 
two were missing exon 7 of the OTC gene and that the other was missing the 
first 12 base pairs of exon 5. Sequencing of genomic DNA from these patients 
revealed that one mutant missing exon 7 had a point mutation causing a T to C 
substitution in the 5’ splice donor site of intron 7. The other mutant missing 
exon 7 had an A to G change in the third position of intron 7. Interestingly, both 
of these mutations resulted in skipping the preceeding exon, rather than 
inclusion of some or all of the affected intron. In the third mutant, an A to T 
substitution was found in the 3’ splice acceptor site at the end of intron 4. Here, 
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a cryptic splice acceptor site within exon 5 was used. Although each of the 
deletions was in frame, Western blotting of liver homogenates from these 
patients with anti-OTC antiserum showed no immunoreactive material. Northern 
blotting of liver RNA from these patients demonstrated reduced, but significant 
amounts of OTC mRNA in one of the patients with a deleted exon, but dramatic 
reduction in OTC mRNA in the other two. We propose that these point 
mutations, which result in abberant splicing of the OTC pre-mRNAs, lead to 
OTC deficiency through either decreased efficiency of mRNA export from the 
nucleus to the cytosol or synthesis of enzyme subunits that are unstable and 
rapidly degraded. These are the first examples of human OTC deficiency 
resulting from mutations that cause production of abnormally spliced mRNAs 
and may represent a common mechanism involved in the pathogenesis of this 
disease. 

THE BIOCHEMISTRY AND MOLECULAR BIOLOGY 
OF ORNITHINE TRANSCARBAMYLASE 
Biochemistry 
Ornithine transcarbamyiase (OTC; carbamoyl-phosphate: L-ornithine 
carbamoyltransferase, EC 2.1.3.3) is the enzyme that catalyzes the second step 
of the urea cycle, the condensation of carbamyl phosphate with ornithine to 
form citrulline, a reversible reaction whose equilibrium favors the formation of 
citrulline. This cycle is the predominant pathway through which ureotelic 
organisms are able to rid the body of excess nitrogenous wastes that would 
otherwise have a detrimental effect, especially upon the nervous system. The 
net effect of this cycle is the incorporation of ammonia nitrogen into urea, the 
main nitrogenous waste product in mammals. The only other known significant 
pathway through which the body can eliminate excess nitrogen is through the 
transamination of alpha-ketoglutarate to glutamate or of glutamate to glutamine. 
Five enzymes, carbamyl phosphate synthetase (CPS), OTC, argininosuccinic 
acid synthetase, arginosuccinate lyase and arginase, function in this cycle and 
are predominantly expressed in liver. CPS and OTC are located subcellularly to 
the mitochondrial matrix; the other three enzymes are cytosolic. 
The pathways of biogenesis and assembly of OTC have been well 
studied in human and rat tissue (Isaya et a/., 1988; Sztul et al., 1987; Norwich et 
al., 1986; Kraus et al., 1988). OTC is translated on free cytosolic ribosomes as 
a 40 kDa precursor protein bearing a 32 amino acid NH2-terminal leader peptide 
which directs uptake of the protein into mitochondria. Like most such leader 
peptides, this region of the OTC precursor contains several basic amino acid 
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residues and an absence of acidic residues. After the OTC precursor is 
translocated across both mitochondrial membranes, the 32 amino acid leader is 
cleaved in a two step process. Several studies have generated mutations in the 
leader sequence and have defined critical residues required for proper 
mitochondria! import and processing (Horwich et a/., 1986; Isaya et al., 1988). 
In particular, it has been found that the arginine residue at position 23 of the 
leader is especially critical for normal processing. Following processing, mature 
36 kDa subunits assemble into homotrimers which comprise the catalytic 
enzyme. 
The complete amino acid sequence of human OTC, as well as that of 
several other species, is known, as deduced from cloned cDNAs and consists 
of 354 amino acids (Horwich et al., 1984). Through comparisons of 
homologies, chemical modification studies, and site directed mutagenesis, it has 
been possible to identify regions of the protein which are involved in different 
functions of the enzyme. In addition, the significant homology between OTC 
and the catalytic moiety of aspartate transcarbamylase (ATC) has allowed 
further speculation regarding regions involved in enzyme function, as E. coli 
ATC has been cloned, crystallized, and characterized much more extensively 
than OTC (Hoover et al., 1983; Kantrowitz and Lipscomb, 1988; Allewell, 1989). 
When regions of homology are aligned, there are 46 residues which are 
completely conserved for OTC across species, of which 30 are conserved in E. 
coli ATC (Kraus et al., 1988). A conserved sequence of phe-leu-his-cys-leu-pro 
is seen at amino acids 300-305 of the human OTC precursor, in which the 
cysteine is believed to be essential to ornithine binding (Marshall and Cohen, 
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1980). A sequence of ser-thr-arg-thr-arg at amino acids 90 to 94 is also highly 
conserved, not only in OTC, but in ATC as well, and is believed to be the 
carbamyl phosphate binding site (Marshall and Cohen, 1980; Kraus et al. 1988). 
The arginine residue at position 92 may be homologous to the arginine at 
position 57 in E. coli OTC which has been determined by X-ray crystallography 
to be involved in isomerization following binding of carbamyl phosphate (Kuo 
and Seaton, 1990). This isomerization is believed to be crucial for the 
subsequent orderly binding of ornithine to occur. Current efforts to further 
characterize crystallized E. coli OTC are under way and it is hoped that similar 
analyses will also be possible for human OTC as well. By elucidating functions 
of other conserved residues in OTC, it is hoped that a better appreciation of 
critical regions of OTC and their functions can be gained. 
Molecular Biology 
The hypothesis that the gene for OTC was on the X-chromosome, which 
was suggested by pedigree analysis of families of patients with OTC deficiency 
in the early 1970’s (Campbell et al., 1971; Short et al., 1973; Palmer et al., 1974) 
received strong support by subsequent demonstration of two populations of 
cells in a liver biopsy from a female heterozygous for OTC deficiency: those with 
OTC activity and those without (Ricciuti et al., 1976). This finding was 
consistent with X-linkage of OTC according to the Lyon hypothesis (Lyon, 
1961), which states that, in females, random inactivation of one of the X- 
chromosomes occurs in various tisues such that they are mosaics of tissue 
expressing either the maternal or the paternal X-chromosome. The further 
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localization of OTC to Xp21.1 using somatic cell hybrids and in situ hybridization 
was performed by Lindgren et al. (1984), 
Rat OTC mRNA was isolated by polysome immunoabsorption, and this 
material was used to prepare rat OTC cDNA clones (Kraus and Rosenberg, 
1982). These rat OTC clones were then used to isolate human OTC cDNA 
(Horwich et al., 1984). Although initially believed to consist of 8 exons covering 
approximately 85 kbp (Horwich and Brusilow, 1989; Hata et al., 1986), recent 
evidence indicates that the human OTC gene consists of 10 exons spanning 
about 73 kbp (Hata et al., 1989). The smallest exon is 54 bp and the largest 
exon (the last one) is believed to be at least 764 bp. Intron sizes range from 80 
bp to 21.7 kbp. The gene produces an mRNA transcript which contains a 1062 
base coding region which is translated into the 354 amino acid OTC precursor 
protein. 
Although Hata et al. (1989) reported a cDNA of 1849 bases, it may be 
that mRNA transcripts of differing lengths are produced, at least in humans. 
Northern blot analysis performed for this thesis, as well as those reported by 
other authors (Grompe, et al.] 1989, Hodges, P.E. unpub. obs.), shows three 
predominant sizes of mRNAs: -3200 bases, -1800 bases, and -1300 bases. 
Available sequence data for the 3’ end of the OTC gene shows several putative 
AATAAA polyadenylation sequences. Relative to the translation start codon, 
these sequences begin at bases 1151, 1408, and 1934. Because they isolated 
a cDNA clone consisting of 1769 bases from the initiation codon, Hata et al. 
(1989) hypothesized that the third polyadenylation sequence was the functional 
signal. However, given the different sizes of transcripts seen on Northern 
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blotting, it may be that at least one of the upstream sequences also functions as 
a polyadenylation signal for some transcripts, in addition to an as yet 
unidentified sequence further downstream. 
The 5’ end of the human OTC gene has been sequenced 665 bp 
upstream from the translation initiation codon (Hata, 1986) in an attempt to 
elucidate sequences in the 5’ flanking sequence which regulate expression. 
Within this region there are two candidates for the CAAT and TATA boxes 
believed to be involved in gene expression. There are CTCAAT and TATAAAT 
at positions -329 to -324 and -285 to -279, respectively, and CAAT and GCATAA 
at positions -252 to -249 and -200 to -195, respectively. In addition, there is the 
well-known viral core enhancer sequence GTGGAAAG at bases -501 to -494. 
Attempts to define the transcription start site have shown that, in fact, there are 
multiple start sites. Using the technique of SI nuclease mapping with primer 
extension, start sites have been identified at nucleotide positions -95, -120, -150, 
-161, and -166 with respect to the translation start codon (West, A., unpub. 
obs.). Given the variable sites at which transcription is initiated, it is difficult to 
ascertain the role played by any specific sequences in the 5’ untranslated region 
in regulation of OTC expression. 
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ORNITHINE TRANSCARBAMYLASE DEFICIENCY 
History 
The first clinical description of inherited disease due to deficiency of OTC 
was that of Russell et al. (1962) who documented two female first cousins who 
presented with vomiting, screaming, lethargy, stupor, and failure to thrive. Both 
patients were found to have high ammonia levels, both in the blood and 
cerebrospinal fluid, as well as cortical atrophy as demonstrated on 
pneumoencephalography. A liver biopsy was obtained from one of these 
patients, and enzyme assay found only 10% of the normal level of OTC, 
whereas the level of CPS was within normal limits. In the years following this 
report, similar descriptions of this disease appeared, in which ammonia in¬ 
toxication due to OTC deficiency explained the patient’s clinical course. 
(Campbell et al. 1973; Levin etal., 1969a; Levin et al., 1969b; Levin et al, 1969c; 
Matsuda et al., 1971; Sunshine et al., 1972). In these patients, however, both 
the character of their illness, as well as the degree of enzyme deficiency, varied 
greatly. It was also noted that almost all of these patients were female. 
Subsequent studies of two different pedigrees revealed that mothers of female 
patients also had reduced activity of OTC, whereas their fathers had normal 
OTC activity (Short et al., 1973; Levin et al., 1969b). These observations of 
mother-to-daughter transmission and mostly female patients led to the original 
proposal that this disease was transmitted as an autosomal dominant, sex- 
limited trait (Levin et al., 1969a). Campbell et al. (1971) subsequently described 
two male siblings who presented with striking hyperammonemia, coma, and 
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death within 3 days of birth. Assay for OTC activity in these patients revealed 
complete absence of the enzyme, whereas activity of the other urea cycle 
enzymes were all within normal range. At that time these were the first reported 
cases of complete OTC deficiency; all previously reported cases had shown 
only partial deficiency. These descriptions of disease led these authors to 
propose that OTC was encoded on the X-chromosome and that mutations in 
this gene could lead to partial deficiency in affected females through 
disadvantageous Lyonization and complete deficiency in hemizygous males. 
This hypothesis was strengthened by study of four kindreds with complete OTC 
deficiency in hemizygous males and partial deficiency in some female probands 
(Short et al., 1973). The hypothesis of X-linked transmission has since been 
borne out by direct demonstration of Lyonization in heterozygotes for OTC 
deficiency (Ricciuti, et al., 1976) and by localization of the OTC gene specifically 
to band Xp21.1 on the X-chromosome (Lindgren, et al., 1984). Since the 
earliest description of OTC deficiency many more cases have now been 
reported, although the true prevalence of the disease in the population is difficult 
to determine because many cases are probably not diagnosed (Walser, 1983). 
Clinical Features of OTC Deficiency 
The clinical severity of ornithine transcarbamylase deficiency is influenced 
by several factors, some of which are still poorly understood. It is believed that 
the severity of disease is primarily related to the degree of hyperammonemia. 
Severe hyperammonemia is also seen in deficiency of some of the other urea 
cycle enzymes, such as CPS deficiency, arginosuccinic acid sythetase 
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deficiency, and arginosuccinase deficiency. Thus, the syndromes in each of 
these diseases are similar. Various authors have divided OTC deficiency into 
different syndromes depending upon period of onset and sex of the patient, 
although it appears most likely that the degree of severity is along a continuum. 
It is presumed that the degree of hyperammonemia is primarily related to the 
degree to which enzyme activity is preserved in vivo, which would most likely 
depend upon presence of a normal allele (in females) and upon the severity of 
the different mutations. 
Clearly, the most important distinction which defines the degree of 
hyperammonemia in OTC deficiency is the sex of the patient. With some 
exceptions, most hemizygous affected male patients experience onset of 
symptoms in the neonatal period with a progressive downhill course, whereas 
heterozygous (carrier) females display a wider variation in onset and severity. 
Male patients with neonatal onset of the disease are usually the term products 
of normal labor and delivery with normal Apgar scores, but within 24 hours to 
several days after birth are noted to have increasing irritability, lethargy, and 
poor feeding. Soon thereafter further symptoms, including vomiting, 
convulsions, grunting respirations, hypotonia, apnea, seizures, and 
hyperventilation may develop, which can rapidly progress to coma and death if 
left untreated. Because of their clinical picture, these infants are often 
misdiagnosed with either sepsis or pulmonary disease, although further workup 
for these causes is usually non-contributory. In most of these cases, 
therapeutic attempts at lowering serum ammonia levels are unsuccessful and 
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the patient’s demise ensues within a short period after the appearance of symp¬ 
toms. 
A number of male patients affected by OTC deficiency have been found 
either to have a more benign course of disease or to be more responsive to 
efforts at therapy. Some of these patients have a normal neonatal period, but 
experience increasingly severe hyperammonemic crises later in infancy or 
during childhood. Likewise, some patients who are aggressively treated 
following birth (usually because of prior information suggesting the diagnosis) 
are able to live beyond the neonatal period, but are subject to periods of 
hyperammonia later in childhood. Often these periods of hyperammonemic 
crisis are precipitated by increases in protein intake, immunizations, infection, or 
surgery. It is believed that these less severe forms of the disease could be due 
to incomplete deficiency of enzyme. Some of these patients have demonstrated 
no OTC activity in vitro, although it may be that the in vitro assay for OTC does 
not completely represent in vivo OTC activity (Krieger et al., 1979). Presuming 
this to be the case, the mutations responsible for these cases may be small 
defects, such as in-frame point mutations, which may alter the enzyme enough 
to reduce activity to levels well below normal, yet not enough to completely 
abolish activity. One interesting case in which OTC deficiency was diagnosed in 
an otherwise normally developing male at age three turned out to be due to 
mosaicism for OTC deficiency, with one population of cells exhibiting a large 
deletion of the OTC gene (Maddalena et al. 1988). Whether such mocaicism 
could account for other male cases with later onset of symptoms remains to be 
seen. 
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Among females who carry a defective allele for OTC, the clinical course 
can range from the severe neonatal course seen in males to absence of 
symptoms (asymptomatic carriers). As for affected males, it appears that the 
severity of disease is related to residual OTC enzyme activity. The amount of 
OTC activity, and hence the severity of disease, is much more variable in 
females due to the random inactivation of the X-chromosome. Females with a 
favorable pattern of inactivation of defective alleles in the liver are less likely to 
experience severe disease and more likely to be asymptomatic carriers. It is in 
females that more of the features of the disease in childhood have been 
described. These include vomiting, screaming, lethargy, headache, slurred 
speech, irritability, agitation, ataxia, muscular rigidity, delayed growth, abnormal 
development, and aversion to protein rich foods. Again, those who have severe 
forms of the disease can progress to coma and death if hyperammonemia 
cannot be controlled. 
Asymptomatic carriers, although seemingly symptom-free, have often 
been suspected of having some of the sequelae of mild OTC deficiency. It has 
been suggested that minor, undetected hyperammonemic episodes may 
progressively impair normal brain development. Some authors have suggested 
that some of these carriers may have lower IQs as a result of these impairments 
(Batshaw et a!., 1980). It has also been suggested that undetected carriers may 
experience frequent "migraine" headaches, and that they may unconsciously 
self-regulate their diets to avoid protein rich foods (Brusilow, 1985). 
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Diagnosis 
Correct diagnosis of OTC deficiency usually begins with the finding of an 
elevated serum ammonia level. The differential diagnosis of hyperammonemia 
includes deficiency of other urea cycle enzymes, transient hyperammonemia of 
the newborn, Reye’s syndrome, and certain organic acidemias. A finding more 
specific for OTC deficiency is an elevated urine orotate, which is believed to 
result from the shunting of unused carbamyl phosphate into the cytosolic 
pyrimidine biosynthetic pathway. A definitive diagnosis of OTC deficiency can 
only be made by assay of OTC activity from biopsied liver, or possibly via small 
intestinal biopsy (Holzgreve and Golbus, 1984). 
With a better understanding of the genetics and biochemistry associated 
with OTC deficiency have come improved methods for establishing carrier 
status and diagnosing OTC deficiency prenatally. Approximately 10% of 
patients affected by OTC deficiency show large deletions at the OTC locus 
(Rozen et al., 1985). Additionally, several pedigrees have shown alteration of a 
Tag I restriction endonuclease site in the OTC coding sequence which 
represents the OTC defect (Maddalena et al., 1988; Hata et al., 1989). For 
families with either of these defects, prenatal diagnosis can be made by direct 
DNA analysis for the defect, using tissue obtained by amniocentesis or chorionic 
villus sampling. For cases of OTC deficiency where such defects are not 
present, prenatal diagnosis rests upon use of restriction fragment length 
polymorphisms (RFLPs). RFLPs have been demonstrated at the OTC locus 
using the restriction endonucleases Msp I, Bam HI, and Taq I (Fox et al., 1986; 
Nussbaum et al., 1988; Rozen et al., 1985; Spence et al., 1989). Combining all 
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of these RFLPs, it has been shown that approximately 80% of female carriers 
are heterozygous for at least one of them. The main limitation of RFLP 
diagnosis is that it does not identify actual mutations in OTC and so is unable to 
account for cases due to spontaneous mutation. In addition, recombination at 
the OTC locus could affect the results of linkage with RFLPs, although the 
frequency of this occurence should be less than 0.1%. 
Crucial to the process of prenatal diagnosis is the establishment of carrier 
status in mothers. This can be done either through pedigree analysis, a protein 
tolerance test, or the recently described allopurinol test (Brusilow and Valle, 
1987). The protein tolerance test involves a nitrogen challenge given as a high 
protein load, followed by measurements of urinary orotate. Orotate levels in 
carriers are often elevated due to the presence of a population of OTC deficient 
hepatocytes in these women. This test is believed to have a false negative rate 
of about 10% (Brusilow and Horwich, 1989). One of the disadvantages of this 
test is the fact that it also is capable of inducing hyperammonemia, and so 
carries the risks associated with periods of hyperammonemia. Recently, the 
allopurinol test has been shown to as reliable as the protein tolerance test, but 
safer because of the reduced risk of hyperammonemia. This test consists of 
the administration of a dose of allopurinol followed by measurements of urine 
orotidine. In this test, oxypurinol monophosphate, a byproduct of allopurinol, 
inhibits orotidine monophosphate decarboxylase, thus reducing the amount of 
orotate which can be metabolized to uridine 5’-phosphate. This results in 
shunting of the increased orotate seen in carriers into orotidine, which can then 
be detected in the urine. 
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In cases where a woman can be established as a carrier of OTC deficien¬ 
cy, but no detectable mutation or RFLP linkage can be found, only two options 
remain. First, fetal sex determination can be carried out with selective 
termination of male fetuses. Alternatively, if the fetus is found to be male, 
biopsy of fetal liver can be performed to assay for OTC activity (Holzgreve and 
Golbus, 1984). Unfortunately, this procedure is associated with a higher risk of 
complications, including fetal loss. It is hoped that in the future techniques will 
be introduced which can allow prenatal diagnosis through direct detection of 
mutations in the OTC gene when other methods are uninformative (Cotton et 
al., 1988; Grompe et al., 1989). 
The establishment of carrier status and prenatal diagnosis are of utility for 
affected families for several reasons. First, in those families in which carrier 
status can be established, the information can be used to make informed 
decisions regarding future pregnancies. In cases where women proceed with 
pregnancy, prenatal diagnosis of affected males can allow these families to 
choose whether they wish to carry an affected child to term or elect to terminate 
pregnancy. The option of pregnancy termination, though controversial, is 
certainly one which has been beneficial to families hoping to avoid many of the 
unfortunate sequelae of bearing a severely OTC deficient child. Even in cases 
where families choose to continue the pregnancy, the information gained from 
prenatal diagnosis can be used to prepare therapeutic interventions as early as 
possible following birth. This information can be especially relevant if the 
diagnosis of a female carrier can be made prenatally. Because many or most 
carriers will be asymptomatic, prompt recognition of carriers can again allow 
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early efforts at treatment which may avoid periods of hyperammonemia which 
could be detrimental to these females during later development. 
Therapy 
Because the severe clinical effects of OTC deficiency are primarily due to 
profound hyperammonemia, effective therapies have been designed with 
reduction of body ammonia as a main goal. Simplistically, this approach takes 
on two forms: aiding excretion of existing stores of ammonia and reducing the 
load of nitrogen taken in. One other goal of treatment is to maintain glutamine 
levels within the normal range, as it has been suggested that hyperglutaminemia 
may signal impending hyperammonemia (Brusilow and Norwich, 1989). The 
simplest efforts at reducing serum ammonia levels consist of restricting dietary 
nitrogen intake. Thus, protein intake is kept at minimal levels (0.7g/kg per day), 
and essential amino acids are added to the diet. Arginine becomes an essential 
amino acid when the urea cycle is not functioning, therefore dietary 
supplementation of arginine is often also necessary. In order to suppress 
endogenous protein breakdown, intravenous glucose can be added to provide 
nitrogen-free nutrition. 
A therapy which exploits alternate pathways of ammonia excretion is 
administration of sodium benzoate and sodium phenylacetate. Both of these 
compounds divert nitrogen from the usual excretion route via urea synthesis. 
The two known alternate pathways of excretion of ammonia involve transamina¬ 
tion of alpha-ketoglutarate to glutamate and of glutamate to glutamine. 
Benzoate functions by conjugating with glycine (a product of glutamine 
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metabolism) to form hippurate, which can be excreted in the urine. Similarly, 
phenylacetate conjugates directly with glutamine to form phenylacetylglutamine, 
which can also be excreted in the urine. Because phenylacetylglutamine 
contains two atoms of nitrogen to hippurate’s one, it has been suggested that 
phenylacetate may be twice as efficient as benzoate, on a molar basis, at 
disposing nitrogen (Brusilow et al., 1984). Severe hyperammonemia and 
hyperammonemic coma require more dramatic treatment. Historically, 
peritoneal dialysis and exchange transfusions have been used in attempts to rid 
the body of excess ammonia. Because exchange transfusions are able to 
remove ammonia only from the vasular space and excess ammonia is 
distributed in the total body water, this method is in fact of limited usefulness. 
More recently, hemodialysis has also been used and has been found to be 
more effective than either exchange transfusion or peritoneal dialysis. In 
addition, peritoneal dialysis takes a longer period of time to remove a given 
quantity of ammonia than hemodialysis. More dramatic yet is the use of liver 
transplantation for patients with severe OTC deficiency; this therapy has only 
been reported for one patient, who has survived for at least one year (Brusilow 
and Horwich, 1989). The recent use of partial liver transplantation from a parent 
to child may also be a therapy of use in the future. Although more aggressive 
attempts at treatment are required to control hyperammonemia in hemizygous 
males and some severely affected females, certain therapies may also be useful 
in preventing minor hyperammonemic episodes in asymptomatic carriers as 
well. Because such episodes in carriers (as well as in affected males) may 
contribute to intellectual deterioration, treatments such as dietary restrictions 
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and benzoate or phenylacetate administration may be appropriate to prevent 
these deleterious effects. 
Pathology 
Although pathologic changes are sometimes seen in livers from females 
heterozygous for OTC deficiency, most severely affected males show no 
characteristic pathologic changes in liver. In females, the most common finding 
is mild portal fibrosis. Other changes seen in these livers include steatosis, 
focal inflammation, and distorted endoplasmic reticulum (Labrecque et al., 
1979). Changes in pathologic brain specimens from patients with OTC deficien¬ 
cy are more common. Because these changes are believed to be due to 
hyperammonemia, similar pathology is seen in other hyperammonemic 
disorders such as CPS deficiency. Patients with acute, severe 
hyperammonemia typically develop brain swelling, dilated ventricles, cortical 
atrophy, metabolic gliosis, and presence of Alzheimer type II astrocytes 
(Kornfeld et al., 1985; Walser, 1983). The brains of longer term survivors of 
such diseases have more variable changes, but usually show some generalized 
gliosis. 

17 
THE MOLECULAR PATHOLOGY OF OTC DEFICIENCY 
Biochemical Variants 
Much of the initial work carried out towards investigation of the enzyme 
defect in OTC deficiency characterized different mutant enzyme variants 
biochemically. It has been observed that some patients with reduced or absent 
OTC activity have mutant enzymes that display abnormal kinetics that may 
account for their deficiency. Several mutant enzymes have displayed abnormal 
pH dependency, whereas others have shown decreased affinity for carbamyl 
phosphate or ornithine (Levin et al., 1969a; Qureshi et a!., 1978; Walser, 1983) 
In addition to these variants, other mutant enzymes have been described with 
increased affinity for ornithine, decreased inhibition by ornithine, and abnormal 
temperature dependence (Walser, 1983). It may be that the types of mutations 
responsible for the different enzyme defects seen are likewise diverse, in cases 
where little or no OTC activity is present, as well as a lack of OTC 
immunoreactive protein (Saheki et al., 1984), the defects involved may be 
mutations affecting larger portions of the coding regions, for example, deletions, 
splicing errors, and nonsense mutations, or mutations which affect sequences 
necessary for efficient initiation of transcription or translation or for post- 
translational transport and processing of the precursor protein. The biochemical 
variants in which the enzyme has altered kinetics may be due to smaller 
mutations, such as point mutations which affect individual protein domains and 
cause the specific changes seen. Identifying the mutations responsible for 
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these defective enzymes may aid in further characterizing the functions 
associated with given residues and domains in the mature enzyme. 
Mutations responsible for OTC deficiency 
To date, few of the mutations responsible for OTC deficiency have been 
well characterized. Unlike autosomal recessively inherited conditions, OTC 
deficiency, as an X-linked lethal disease, may result from a larger variety of 
different mutations (Haldane, 1935). In some patients studied, the OTC gene 
has demonstrated gross deletion or rearrangement. Most of these mutations 
are partial deletions of the OTC gene, but cases of complete deletion of the 
entire OTC gene have been seen (Levy, 1987; Rozen et al., 1985; Brusilow, 
pers. comm.). Such patients are not believed to be responsible for more than 
10% of OTC patients, however. 
Several point mutations have been identified in unrelated patients which 
alter a Tag i restriction endonuclease site in exon 5 of the OTC coding region 
(Maddalena et al., 1988; Hata et al., 1989). Two of these patients display an A 
to G missense mutation in which a glutamine is substituted for the arginine 
normally present at amino acid position 141 of the OTC precursor. The other 
mutation, also seen in two unrelated patients, is a C to T transition at the same 
codon which generates a stop codon. This area may be susceptible to 
mutation because of the presence of a CpG dinucleotide, for which a higher rate 
of mutation has been observed. This higher susceptibility to mutation is 
believed to be due to methylation of cytosine, with subsequent deamination to 
form thymidine (Youssoufian et al., 1988). Both of these mutations may involve 
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C to T transitions, on either the sense or antisense strand. Grompe et al. 
(1989) used the newly described method of chemical mismatch cleavage 
(Cotton et al., 1988) to analyze amplified cDNAs prepared from patients affected 
by OTC deficiency. This technique detected single base changes in four 
patients which are believed to represent the basis of the observed enzyme 
deficiency. Of the patients described, two had single missense mutations, one 
had a nonsense mutation, and one displayed two missense mutations. Interest¬ 
ingly, one of the missense mutations involved the 5’ splice donor consensus 
sequence at the end of exon 1, possibly making it less suitable for normal 
splicing. Whether the enzyme deficiency in this patient was due more to effects 
of the amino acid change on the protein or to decreased mRNA levels as a 
consequence of reduced normal splicing is uncertain. 
Mutations have also been described which account for two murine 
models of OTC deficiency: sparse fur, and sparse fur-ash. Sparse fur mice 
exhibit decreased OTC activity at physiologic pH, but actually have 150% normal 
OTC activity at alkaline pH. In addition, these mice have greater than normal 
amounts of OTC present in liver. The mutation causing this phenotype has 
been characterized and involves a C to A transversion resulting in substitution of 
an asparagine residue for a histidine at amino acid position 117 (Veres et al., 
1987). The other mouse model, sparse fur-ash, which also exhibits abnormal 
skin and hair, displays a reduced level of enzyme activity and cross -reactive 
material. The mutation identified in these animals is a G to A missense mutation 
in the last position of exon 4, which is similar to the defect in human OTC 
described above (in which the splice donor sequence at the end of exon 1 is 
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altered) in that the defect also involves a 5’ splice donor sequence (Hodges and 
Rosenberg, 1989). In addition to causing an amino acid substitution and 
reducing levels of mRNA, this mutation also activates a cryptic 5’ splice donor 
sequence in intron 4. This results in the production of an elongated mRNA 
containing some sequence from intron 4, in addition to normal length mRNA, 
both of which are present at much reduced levels compared to normal. 
With the advent of the polymerase chain reaction (Mullis and Faloona, 
1987; Saiki et al., 1988), which has greatly simplified many aspects of molecular 
analysis, it can be expected that molecular defects in a broad range of diseases 
will be revealed at an increasing pace. Much as the method of site directed 
mutagenesis has been employed to define critical regions of proteins required 
for proper synthesis and function, analysis of mutations causing disease can aid 
in the process of characterizing structure-function relationships for different 
proteins. In addition, by identifying regions which are especially prone to 
mutation, such analyses may facilitate improved methods of diagnosis through 
direct mutational analysis. Because diagnosis of inherited disease often relies 
upon linkage, which may be difficult to establish, and because (especially for X- 
linked diseases) new mutations may account for a substantial number of cases, 
improved methods of direct analysis of mutations are desired. Recently 
developed techniques, such as chemical mismatch cleavage (Cotton et al., 
1988) may facilitate easier direct mutational analysis in the future. 
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CASE HISTORIES 
In the following section case histories are provided for those patients in 
whom mutations believed to represent the cause of OTC deficiency were 
identified. Each of these patients succumbed to hyperammonemia that was 
subsequently attributed to OTC deficiency on the basis of a liver assay for OTC 
activity. 
Case 1 
Patient OW was the male product of a pregnancy which was believed to 
be at or near term, although the mother’s LMP was uncertain. Gestation was 
remarkable for maternal use of alcohol, tobacco, marijuana, and cocaine, but 
was without complications. Birth was by spontaneous vertex delivery and Apgar 
scores were 7 and 8 at 1 and 5 minutes, respectively. Shortly following birth he 
developed tachypnea and grunting which improved on 30% oxygen. The next 
day tachypnea recurred at a rate of 80 respirations per minute and at 40 hours 
he had a 6 minute generalized seizure associated with a temperature of 102.6°F. 
Chest X-ray was unremarkable. Ampicillin and gentamicin were started for 
presumed sepsis. At 43 hours, he was transferred to the neonatal unit and 
intubated due to prolonged apnea and repeated seizures. An ammonia level 
which was drawn at 24 hours was significantly elevated to 990 /xg/dl (normal 
serum ammonia values in newborns are 110-180 /xg/dl). A metabolic error was 
considered at this time. Peritoneal dialysis was started with some improvement 
of hyperammonemia to 330 on day 3. He continued to be unresponsive, 
however, and was maintained on a respirator. On day five he was extubated 
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after he had some improvement in level of consciousness, but his ammonia 
level, though improved, was still elevated to 160 one week after delivery. 
Further laboratory tests revealed elevated serum glutamine and elevated urine 
orotate. He was started on a protocol to reduce serum ammonia using 
benzoate and also continued to receive peritoneal dialysis, but after 4 weeks his 
hyperammonemia continued and he again required use of a respirator. At this 
point he was taken off the protocol and dialysis at the parents’ request, and, 
interestingly, his ammonia then fell to 100. Unfortunately, he continued to do 
poorly and 10 weeks after birth he developed tachycardia and died. The 
patient’s mother was of Asian descent and his father was black. Family history 
was remarkable for a maternal cousin who carried a diagnosis of multiple 
carboxylase deficiency. A subsequent pregnancy by the mother ended in 
miscarriage. 
Case 2 
RD was a white male product of a full term pregnancy with minor com¬ 
plications including headaches, first trimester spotting, and iron deficiency 
anemia. He was the first pregnancy of the mother and was delivered vaginally 
without complications. At 24 hours he was noted to feed poorly, and at 48 
hours was in hyperammonemic coma with an ammonia of 4000 ^g/dl. After 
transfer to a tertiary care hospital, he was treated with peritoneal dialysis. On 
the basis of elevated urine orotate and other metabolic screening, he was given 
a diagnosis of ornithine transcarbamylase deficiency, although liver assay was 
not performed. Management with dialysis and nitrogen-free essential amino 
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acids reduced his ammonia to less than 100. He was able to be discharged at 
3 months with the ability to cry and suck and was maintained on a restricted 
protein diet of 1 to 1.5 gm of protein per day. He was developmental^ retarded 
following discharge, being minimally responsive, and had daily myoclonic 
seizure activity which could not be controlled by anticonvulsants. Although he 
was maintained predominantly by dietary management only, he required almost 
monthly admission for hyperammonemia, which was usually heralded by 
vomiting and protein intolerance requiring cessation of all dietary protein. At 15 
months of age the patient was admitted for a trial of phenylacetic acid and 
benzoate management, which was of some aid in reducing serum ammonia. 
His subsequent course continued to be downhill, and at 18 months of age he 
became hypotensive in the intensive care unit and succumbed to 
cardiopulmonary arrest. Family history was unremarkable for neonatal death or 
miscarriage. The patient’s mother reported a history of recurrent headaches. 
Upon protein loading she experienced a headache and had increased urinary 
orotate, consistent with carrier status for OTC deficiency. A subsequent 
pregnancy by the mother yielded an affected hemizygous male who was treated 
starting at birth with reasonable control of hyperammonemia; the child is 
reportedly growing and developing reasonably well at 5 months. 
Case 3 
Unfortunately, the clinical information regarding this patient is extremely 
limited due to difficulties in obtaining relevant data from the original referring 
physician. What is known is that he died in the newborn period, most likely at 
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around 48 hours of age, with very high plasma ammonium levels, and had an 
elevated urinary ©rotate. 
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MATERIALS AND METHODS 
RNA Preparation 
Total human liver RNA, preserved at -80°C prior to use, was prepared by 
the guanidine thiocyanate extraction procedure as described (Chirgwin et al., 
1979). Guanidine thiocyanate was purchased from Eastman Kodak Company; 
guanidine hydrochloride and 30% Antifoam A were obtained from Sigma. The 
total RNA recovered was dissolved in diethylpyrocarbonate-treated water. 
DNA Preparation 
Genomic DNA was prepared by homogenizing liver in lysis buffer (200 
mM Tris, pH 8.0, 100 mM EDTA, 1% SDS, 100 nQ/m\ proteinase K)(20 ml/g 
liver) and incubating overnight at 50°C with shaking. This solution was extracted 
with an equal volume of phenol: chloroform: isoamyl alcohol (25:24:1), followed 
by extraction with chloroform: isoamyl alcohol (24:1) alone. DNA was precipitat¬ 
ed with 1/10 volume sodium acetate and 2 volumes of ethanol, washed with 
70% ethanol, lyophilized, and resuspended in RNase digestion buffer (50 mM 
Tris-CI, pH 8.0, 10 mM EDTA, 10 mM NaCI, 100 Mg/ml RNase A)(0.5 ml/g liver). 
After 3-4 hours digestion at 37°C, the solution was extracted as described 
above and dialyzed overnight at 4°C vs. 10 mM Tris-CI, pH 8.0, 1 mM EDTA. 
Reverse Transcription 
Five micrograms of total RNA in a volume of 22.5 /J were heated to 80°C 
for 3 min, then reverse transcribed in a reaction mixture containing 50 mM Tris- 
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Cl, pH 8.3, 75 mM KCI, 10mM MgCI2, 4.35 mM dithiothreitol, bovine serum 
albumin at 0.175 mg/ml, 0.5 mM of each deoxyribonucleoside triphosphate, 
1.25 Units RNasin (Boehringer Mannheim or Promega), 70 Units AMV reverse 
transcriptase (Boehringer Mannheim), and 70 ng IXaR reverse primer (5’-CAAT- 
GGCAAAGCATATCATA-3’) in a total volume of 50 /J. A similar reaction was 
carried out using P2, a reverse primer for 6-propionyl CoA carboxylase (3-PCC) 
whose sequence was 5’-AGGCCTTCCTGGTGATGACTGTGAC-3’. Each 
reaction was incubated at 44°C for one hour; an additional 40 Units RNasin and 
20 Units of reverse transcriptase were added, and the incubations were 
continued at 44°C for another 40 min. The cDNA samples were frozen at -20°C 
until used in PCR amplification. 
PCR amplification of cDNA and genomic DNA 
Reactions were done in a total volume of 100 /J, essentially as described 
(Saiki et a/., 1988). To a 5 /J aliquot of each reverse transcription mixture was 
added 10 y\ 10X reaction buffer (0.5M KCI, 100 mM Tris-CI, pH 8.3, 15 mM 
MgCI2, gelatin at 200 /ig/ml), 16 /J dNTP mixture (1.25 mM each), 5 /zl each of IL 
and IXaR (or PI and P2 when amplifying a region of 8-PCC cDNA) primers (20 
mM), 2.5 Units Taq DNA polymerase (United States Biochemical Corp.), and 
HaO. The sequence of IL primer is 5’-GGGCATAGAATCGTCCTTTA-3’ and that 
of PI is 5’-TCCAATATTCCACTCATCAC I I I iG-3’. Each sample was overlaid 
with 100 mineral oil to prevent evaporation. The IL and IXaR primers for OTC 
were selected because they yielded a 1242 bp product which covered the entire 
1062 bp coding region of OTC. The PI and P2 primers amplified a 150 bp 
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fragment within the coding region of B-PCC. Amplification conditions consisted 
of an initial denaturation at 94°C for 5 min., followed by 40 to 50 cycles of 
denaturation at 94° for 2 min., annealing at 55° for 2 min., and extension at 72° 
for 3 min. Aliquots were analyzed on 1% SeaKem or SeaPlaque agarose (FMC 
Bioproducts). 
Genomic amplifications were performed similarly, except that 1 ng of total 
genomic DNA was used as template. Primers used were VL (5’-TCi I I I iCT- 
TGGTTTACCAC-3’), VR (5’-GTAAGACAAATAAATAAACC-3’), VIIL (5’-TTTAAA- 
TTCCTTCCTCCTTT-3’), and VIIR (5’-CCTGAGAGAGCATCAATTTG-3’). VL and 
VR amplified all of exon 5 as well as the flanking portions of intron 4 and intron 
5. VIIL and VIIR yielded amplified exons 7 and 8, all of intron 7, and flanking 
portions of intron 6 and intron 8. Products were analyzed on 3% NuSieve 
agarose (FMC Bioproducts). 
Agarose Gel Electrophoresis 
Electrophoresis of DNA samples on agarose gels was done in either TAE 
(0.04 M Tris acetate, 0.001 M EDTA) or TBE (0.089 M Tris-borate, 0.089 boric 
acid, 0.002 M EDTA) buffer containing 0.35 ug/ml of ethidium bromide. DNA in 
the gels was then visualized and photographed under UV light. Samples were 
added to loading buffer (0.025% bromophenol blue, 0.025 xylene cyanol, and 
5% glycerol) and electrophoresed at constant voltage. 
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Restriction Endonuclease Digestion, Cloning, and Sequencing of PCR 
products 
Following each amplification reaction, samples were extracted and 
ethanol precipitated as above and resuspended in an appropriate volume of 10 
mM Tris-CI, pH 7.5, 1 mM EDTA. Aliquots were taken for restriction endo¬ 
nuclease digestion under conditions described by the manufacturer (Boehringer 
Mannheim or New England Biolabs). 
Subcloning of PCR products was carried out by standard methods 
(Maniatis, et al., 1982) using pBluescript KS (Stratagene) as a vector. PCR 
products were either phosphorylated with T4 polynucleotide kinase (Promega) 
(for direct blunt-ended ligation) or digested with restriction enzymes (for 
cohesive end ligation) prior to incubation with T4 DNA ligase (New England 
Biolabs) and the appropriately digested vector. Digested vectors with blunt 
ends were treated with calf intestinal phosphatase (Boehringer Mannheim) 
before ligating. Both DNA inserts and vector were purified by agarose 
electrophoresis, followed by recovery by electroelution as described (Maniatis et 
al., 1982). Ligations were carried out at 16°C (cohesive end ligation) or room 
temperature (blunt-ended ligation) for 12-20 hours using 200 ng of vector DNA 
and a several-fold molar excess of insert. Aliquots were taken from ligation 
mixtures and used to transform DH5-a cells (Bethesda Research Labs) 
according to the supplier’s protocol. Cells were plated on LB (Luria Broth) 
plates containing 50 ug/ml ampicillin, 0.01 M MgS04, 0.2 mM isopropyl-B-D- 
thiogalactopyranoside (IPTG) and 0.04 ug/ml 5-bromo-4-chloro-3-indoyl B-D- 
galactopyranoside (X-gal) for blue-white color selection of recombinant colonies. 
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Minipreparations of DNA of selected colonies (Birnboim and Doly, 1979) were 
analyzed by restriction digestion and subjected to dideoxynucleotide sequencing 
using Sequenase (United States Biochemical) according to the supplier’s 
specifications. Samples from sequencing reactions were boiled 3-5 minutes and 
electrophoresed on 6-8% denaturing acrylamide gels in TBE buffer using 60-70 
Watts at constant power. Gels were fixed in 10% methanol, 10% acetic acid for 
60-90 minutes, dried, and exposed to XAR-5 film at room temperature. 
Northern Blotting 
10 /xg of total liver RNA was electrophoresed on a 1.1% agarose gel in 
formaldehyde as described (Maniatis, et al., 1982). Following electrophoresis 
the gel was soaked 30 min. in 10X SSC (IX SSC is 150 mM NaCI, 167 mM Na- 
Citrate, pH 7.0) and then directly transferred to nitrocellulose as described. The 
filter was baked 2 hours under vacuum at 80°C. Filters were prehybridized in 
50% formamide, 5X SSC, 5X Denhardt’s solution (IX Denhardt’s solution is 
0.02% each of Ficoll, polyvinylpyrrolidone, and bovine serum albumin in H20), 
50 mM Na2P04 (pH 7.0), and 250 ug/ml sheared salmon sperm DNA for 3-6 
hours at 42°C. Filters were hybridized with 32P labeled cDNA probes prepared 
by the oligolabelling method (Feinberg and Vogelstein, 1984) using a priming kit 
(Boehringer Mannheim) according to the supplier’s recommendations. Material 
for oligolabelling was prepared by PCR amplification of cDNAs from plasmids. 
Generally, 100-150 ng of this material to be used as a probe was used in the 
oligolabelling reaction. Using this method, 1 to 2 x 108 cpm/ug probe was 
obtained. Unincorporated nucleotides were removed by spun-column 
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chromatography, and probes were boiled 5 minutes before adding to 
hybridizations. Hybridization was carried out in 50% formamide, 5X SSC, 5X 
Denhardt’s solution, 20 mM NajPC^ (pH 7.0), 10% dextran sulfate, and 75 ug/ml 
sheared salmon sperm DNA at 42°C for 12-20 hours. Filters were washed 10 
minutes with 2X SSC, 0.1% SDS at room temperature, then 30-60 minutes in 
0.1X SSC, 0.1% SDS at 50-55°C. Filters were exposed to XAR-5 film with an 
intensifying screen at -70°C for one day to one week. Following hybridization, 
filters were washed in 2 mM Tris-HCI, pH 8.0, 1 mM EDTA, and 0.1% SDS for 
20-30 minutes at 60°C, after which they could be reused. 
Immunoprecipitation and Western Blotting 
Liver tissue was homogenized in NETS buffer (150 mM NaCI, 0.5% Triton 
X-100, 10 mM EDTA, 0.25% sodium dodecyl sulfate) as a 10% (w/v) solution. 
Homogenates were centrifuged at 8,000 rpm in an SS-34 rotor (Sorvall) to 
remove insoluble materials, and 100 pi of this homogenate (10 mg liver) was 
used for immunoprecipitation. Five pi each of anti-OTC and anti-methylmalonyl- 
CoA mutase ("mutase") antiserum were added to the homogenates, and the 
solutions were rocked overnight at 4°C. Immune complexes were recovered by 
incubation with 50 pi 10% (w/v) Staphylococcus aureus cells (Bethesda 
Research Labs) and centrifugation (Kessler, 1981). The S. aureus cells were 
washed five times with 1.0 ml of RIPA buffer (10mM Tris-CI, pH 7.4, 150 mM 
NaCI, 0.1% SDS, 1.0% Triton X-100, 1.0% sodium deoxycholate), and the 
immunoprecipitated proteins were vortexed into 40 ul loading buffer (62.5 mM 
Tris-CI, p 6.8, 2.0% SDS, 10% glycerol, 5.0% B-mercaptoethanol, 0.001% 
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bromophenol blue) and boiled for 5 min. (Kessler, 1981). Supernatants were 
loaded onto an SDS-polyacrylamide gel according to Laemmli (1970). The 
stacking gel consisted of 3.8% acrylamide/0.16% bis-acrylamide and the 
running gel, 8% polyacrylamide/0.34% bis-acrylamide. After electrophoresis, 
the gel was placed in electroblotting transfer buffer (20 mM Tris, 150 mM 
glycine, 20% methanol) for about 10 minutes, and then electroblotted onto 
nitrocellulose at 100 milliamperes overnight as described (Towbin et al., 1979). 
The filter was soaked in a solution of 5% Carnation dry milk in PBS buffer (0.8% 
NaCI, 0.02% KCI, 0.115% Na2HP04, 0.02% KH2P04) for 2-3 hours, then 
transferred to 50 ml of a solution of 13% bovine hemoglobin and 0.02% sodium 
azide in PBS to which 500 ^1 of both anti-OTC and anti-mutase antiserum had 
been added. The filter was washed in PBS for ten minutes twice, then washed 
in PBS with 0.5% Nonidet P-40 for ten minutes two more times. The filter was 
soaked in 50 ml of 5% Carnation dry milk in PBS containing 50 n\ [125 l]-protein 
A. Washes in PBS and Nonidet P-40 were repeated as above, after which the 
filter was exposed to Kodak XAR-5 film with intensifying screens at -70°C. 
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RESULTS 
Amplification of cDNAs prepared from patient livers 
To detect mutations within the 1062 base coding sequence of OTC, RNA 
was isolated from eleven livers taken at autopsy from male patients found to 
have OTC deficiency by assay of OTC activity and was used to synthesize 
single stranded cDNAs. This material was subjected to PCR amplification using 
a set of primers which yielded a 1242 bp product from normal subjects that 
included the entire coding region of the OTC cDNA (Figure 1). In seven of the 
patients studied, cDNA products were observed following PCR amplification and 
agarose gel electrophoresis. A control cDNA template, pH0731 (Horwich et a/., 
1984), was used for comparison. Three of these seven cDNAs were found to 
be shorter than the normal cDNA (Figure 2). The other four appeared to be of 
normal length (not shown). In order to determine whether the inability to amplify 
cDNA from the other four patients was due to lack of OTC expression or overly 
degraded RNA, a second amplification was performed using primers for a 150 
bp segment of B-propionyl CoA carboxylase (B-PCC) cDNA. As seen in Figure 
3, two of the patients in whom no OTC cDNA could be demonstrated yielded 
clear bands corresponding to amplified B-PCC cDNA. Thus, it appeared that 
these patients did not express sufficient OTC mRNA to be amplified, while in the 
other two samples it seemed that degradation of the RNA made them 
uninformative in this analysis. 
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Localization of deletions in cDNAs by restriction enzyme analysis 
Amplified cDNAs were subjected to digestion with restriction endo¬ 
nucleases in order to localize the regions in the coding sequence from which 
sequences were missing, as well as to look for smaller deletions which may not 
have been apparent in the full length products. Separation of restriction 
fragments on NuSieve agarose revealed that, in one patient, there was a 
deletion in the cDNA of approximately 10-15 bp located between the unique Acc 
I and Xho I sites (Figure 4). In the other two patients, similar analyses showed 
deletions 5’ to the Asp 718 (Kpn I) site and 3’ to the most distal Hae III site 
which removed an Msp I site and approximately 50 bp of the cDNA (Figures 5 
and 6). Figure 7 shows cleavage sites of restriction enzymes used to localize 
cDNA deletions and the normal expected band sizes for the digests performed. 
The apparently full length cDNAs from the other four patients from whom these 
amplified cDNAs could be produced showed no evidence of deletions (data not 
shown). 
Identification of mutations at the cDNA level by DNA sequencing 
In order to characterize the mutations in those three patients in which 
they could be localized, appropriate regions of PCR amplified cDNA were 
subcloned and sequenced. As shown in Figure 8, the mutation in patient OW 
between the Acc I and Xho I site was found to be a 12 bp deletion 
corresponding to the first 12 base pairs of exon 5. No other changes in 
sequence were found. Thus, the net effect of the mutation was an in-frame 
excision of nucleotides coding for 4 amino acids (val-leu-ser-ser) in the mature 
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protein. In the other two patients, sequencing of the relevant portion of the 
cDNAs demonstrated that both were missing the 54 base pairs which 
correspond to exon 7 (Figure 9). Again, the mutation observed was an in-frame 
cDNA deletion with no evidence of other changes. These cDNA deletions are 
shown schematically in Figure 10. In all three cases, the sequencing results 
suggested that RNA splicing errors were responsible for the enzyme defects. 
Identification of mutations in genomic DNA by DNA sequencing 
In order to characterize mutations in the genomic DNA which could have 
led to the presumed abberant splicing, two sets of primers were chosen which 
corresponded to intron sequences flanking the exons involved. These primers 
were used to amplify the regions of interest from genomic DNAs isolated from 
patient livers, and the fragments were subcloned and sequenced using a 
protocol similar to that used to sequence the cDNAs. 
In patient OW, whose cDNA was missing the first 12 bp of exon 5, 
sequencing of genomic DNA revealed that the flanking sequence of intron 4 
contained a point mutation substituting a T for the A in the AG dinucleotide that 
normally ends introns (Figure 11). Because the splicing system in primates 
requires introns to begin with GT and end with AG for proper splicing to occur 
(Breathnach and Chambon, 1981; Mount, 1982), it was likely unable to 
recognize the normal intron 4/exon 5 splice junction in this patient’s precursor 
RNA and instead utilized a nearby cryptic splice site within exon 5 which 
conformed to the "GT-AG rule" for correct RNA splicing. Thus, the deletion seen 
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at the cDNA level resulted from a point mutation within the 3’ splice acceptor 
site which led to abberant splicing. 
In the two patients missing exon 7, two different point mutations were 
found in genomic DNA which may have caused abnormal splicing. In both 
patients, no sequence abnormalities were observed in the 3’ splice acceptor 
region at the intron 6/ exon 7 junction. On the other hand, point mutations 
were seen in the 5’ splice donor region around the exon 7/intron 7 junction. In 
one patient, the mutation was a substitution of a C for the T in the initial 
dinucleotide of intron 7, changing GT to GC (Figure 12). This mutation also 
violated the GT-AG rule referred to above and likely made the normal 5’ splice 
donor region unsuitable for use in joining exon 7 to exon 8. The other patient 
had an A to G substitution in the third position of intron 7 (Figure 13). Although 
this point mutation does not involve the invariant GT of the splice donor, it does 
affect the established consensus sequence for 5’ splice donors. It should be 
noted that both of these mutations cause the preceding exon to be skipped, 
even though the 3’ splice acceptor which would function to join exon 6 to exon 
7 is unchanged. No evidence was seen in the cDNA sequences to suggest 
either that normal splicing occurred or that a cryptic 5’ splice donor site within 
exon or intron 7 was activated in these patients. 
Quantitation of OTC mRNA by Northern Analysis 
Analysis of patient livers to determine the amount of OTC mRNA was 
carried out to determine whether any of these OTC deficiencies were associated 
with reduced amounts of message. This was of particular interest for those 
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patients with splicing defects, as it was desirable to know if the abberant splicing 
was also carried out at reduced efficiency. RNA samples prepared from patient 
and control liver were probed with a nearly full length OTC cDNA obtained by 
amplifying an OTC cDNA template with the IL and IXaR primers described 
previously. After exposure, the filter was washed and rehybridized with a probe 
containing about 300 bases of coding sequence for methylmalonyl-CoA mutase 
as an internal control. Figure 14 shows Northern blots obtained after probing 
for both OTC and mutase. Among the patients with splicing errors, patient MC 
contains a significant, although decreased, amount of OTC mRNA compared to 
normal, whereas patients RD and OW have minimally detectable levels of OTC 
mRNA. Of the remaining patients, one actually appears to have normal to 
increased amounts of OTC message, whereas two others have reduced levels 
of expression. One of these samples contained no bands for either OTC or 
mutase (presumably because of RNA degradation) and thus was uninformative. 
Analysis of liver homogenates for OTC cross-reacting material 
In order to assess the effects of these mutations at the protein level, we 
assayed immunologically for OTC cross-reacting material in patient liver tissue. 
Homogenates were prepared from liver and immunoprecipitated with a 
polyclonal anti-OTC antiserum, as well as with an antiserum against 
methylmalonyl-CoA mutase as a control. Immunoprecipitated material was then 
electrophoresed on an SDS-polyacrylamide gel, blotted onto nitrocellulose, and 
probed with anti-OTC and anti-mutase antisera. As shown in Figure 15, a 
homogenate prepared from liver of a patient unaffected by OTC deficiency 
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(lanes 1 and 2) yielded clear bands corresponding to both the 36 kDa mature 
OTC subunit and the 77.5 kDa mutase protein. Liver from each of the patients 
with OTC deficiency also showed clear evidence of material cross-reacting with 
mutase, but none of the samples for which the defect is described 
demonstrated a band corresponding to mature OTC or to the shorter proteins 
predicted from the deletions, even when the filter was exposed for as long as 10 
days. Of the other four patients from whom full length cDNA could be amplified, 
one displayed a minimal amount of OTC cross reacting material, the others had 
none. Thus, although these splicing mutations produced in-frame alterations in 
the OTC mRNA, no cross-reactive OTC protein could be identified in the livers 
from these patients. The molecular defects in the other four patients remain to 
be defined. 
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DISCUSSION 
We were able to amplify cDNAs containing the coding region of the OTC 
mRNA from liver tissue of seven of eleven 11 male patients with OTC deficiency. 
Among these seven patients, we detected and identified RNA splicing errors 
believed to be responsible for clinical OTC deficiency in three. These mutations 
are single base changes altering the highly conserved sequences seen at 
intron-exon boundaries and prevent the splicing apparatus from properly 
recognizing and acting at the normal splice junctions. One of these mutations is 
a single base alteration (A^T) in the 3’ splice acceptor AG dinucleotide at the 
end of intron 4, making this region an unacceptable splice junction. As a result, 
a cryptic 3’ splice acceptor within exon 5 is used, producing a deletion of the 
first 12 base pairs of exon 5 in the resulting mRNA. The other two mutations 
both involve the deletion of exon 7 from the mRNA as a result of point mutations 
within the 5’ splice donor sequence at the junction between exon 7 and intron 7. 
One of these mutations changes the second base of intron 7 such that the GT 
dinucleotide becomes GC, whereas the other one changes the A in the third 
position of the intron to a G. Both of these mutations result in skipping the 
preceding exon, even though the preceding 5’ and 3’ splice consensus 
sequences are apparently intact. 
The conserved sequences present at 5’ and 3’ splice junctions that are 
required for correct splicing have been characterized by several authors 
(Breathnach and Chambon, 1981; Mount, 1982; Ohshima and Gotoh, 1987; 
Shapiro and Senepathy, 1987; Aebi eta!., 1986). By analyzing a large number 
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of eukaryotic splice junction regions, consensus sequences have been 
established which determine the suitability of these regions to function in normal 
splicing. For 5’ splice donors, a 9 base consensus sequence of ^ AG:GTq AGT 
has been established (Mount, 1982), although some authors do not include the 
first nucleotide in this consensus (Shapiro and Senepathy, 1987). This 
sequence is notable for its ability to form base pairs with the sequence 
ACv>MCCUG of UI-snRNA that binds to 5’ splice donors during the splicing 
process (Mount et al., 1983). Similarly, a consensus sequence of (Py)n>10 
AG:G has been given for 3’ splice acceptor sites. Within these consensus 
regions, the dinucleotides GT for 5’ donors and AG for 3’ acceptors have been 
shown, with few exceptions, to be invariant and required for correct splicing (the 
"GT-AG rule"; Breathnach and Chambon, 1981; Mount, 1982). A scoring 
system has been descibed (Shapiro and Senepathy, 1987) which gives a 
numerical value for any proposed 5’ or 3’ consensus sequence, based on the 
frequency of each nucleotide in normal splice sequences. Using this system, 
the consensus sequences AG:GTAAGT and PyPyTTPyPyPyPyPyPyNCAG:G 
yield a score of 100, and most splice sequences normally used have a score 
greater than 70. 
Figure 16 shows the scores for the normal splice sites and the mutant 
ones detected in this group of patients, as well as for the proposed cryptic site 
within exon 5. The mutations in patients OW and RD, which involve the highly 
conserved AG and GT dinucleotides, respectively, significantly reduce the 
scores for these sequences. In patient MC, on the other hand, the A^G 
mutation in the third position of intron 7 produces only a slight reduction in the 
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score. It is interesting that such a mutation leads to abnormal splicing, as 
demonstrated in this patient, even though it might be predicted that normal 
splicing could still occur at this site. In some ^-thalassemia patients, for 
example, point mutations in the consensus sequence outside of the terminal 
dinucleotides give rise to aberrantly spliced products, as well as to some 
normally spliced ones (Kazazian and Boehm, 1988; Treisman et a/., 1983; 
Atweh, et al., 1987). We see no evidence, however, of any normally-spliced 
OTC mRNA from patient MC upon agarose gel analysis of PCR amplified cDNA 
(see Figure 2 right, lane 3). 
Several papers and reviews have described the current model of a 
spliceosomal complex which is involved in the process of splicing primary 
transcripts into mRNAs that are then exported to the cytoplasm (Sharp, 1987; 
Green, 1986; Padgett etal., 1986; Steitz, 1988; Maniatis and Reed, 1987;). 
Although the understanding of the pathway of RNA splicing is still in evolution, 
the general mechanism which has been proposed suggests the formation of a 
spliceosomal complex containing the small nuclear ribonucleoproteins 
(snRNPs), U1, U2, U4, U5, and U6, and newly-transcribed RNA, which is 
involved in recognition and splicing at appropriate 5’ and 3’ sites. An early step 
in the splicing process is believed to involve recognition of a 5’ splice donor by 
U1 snRNP via base pairing with the homologous region of U1 (Lerner et al., 
1980; Zhuang and Weiner, 1986; Mount et al., 1983). U2 and U5 snRNPs are 
believed to participate in recognition at the 3’ end of an intron, followed by the 
addition of U4 and U6 (usually associated as one particle, U4 + U6) and final 
spliceosome assembly (Maniatis and Reed, 1987; Sharp, 1987). The U5 particle 
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is postulated to be involved in recognition at the 3’ splice site, and U2 
recognizes a weakly conserved branch sequence located about 20 to 40 bases 
upstream of the 3’ splice site. Once assembly of the spliceosome has 
occurred, the excision of intronic sequence and joining of the exons occurs as a 
two step process. First, the 5’ splice site is cut, followed by formation of a lariat 
structure in which the branch site is joined to the excised upstream end of the 
intron (Sharp, 1987; Reed and Maniatis, 1985). Then, in the second step, the 
exons are joined as the intron is cut at the 3’ splice site and released as a lariat. 
How this mechanism functions to appropriately excise all introns from 
genes containing multiple introns has not been established. Initially, a 5’ to 3’ 
directional scanning model was proposed (Lang and Spritz, 1983) in which the 
spliceosomal complex moved linearly along the pre-mRNA, selecting 5’ and 3’ 
splice sites as it proceeded. Such a model is unable to explain the exon 
skipping described in two patients here, however, in which mutations in 5’ splice 
donors cause skipping of the previous exon. Similar effects have also been 
seen in certain patients with phenylketonuria (Marvit et al., 1987), Ehlers-Danlos 
syndrome (Weil et al., 1988), leukocyte adhesion deficiency (Kishimoto, et al., 
1989), APRT deficiency (Hidaka et al., 1987), and acute intermittent porphyria 
(Grandchamp et al., 1989), as well as in the hamster dihydrofolate reductase 
gene (Mitchell et al., 1986). A similar mutation was also seen in one of the 8- 
thalassemias, but in this case another RNA species was also produced in which 
a cryptic 5’ splice site in the intron was used (Treisman et al., 1982). Whatever 
model of splicing is proposed would need to show how, in such mutants, the 
preceding exon could be spliced out, even though the preceding 5’ and 3’ 
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splice sequences are intact. Marvit et al. (1987) have proposed that cooperative 
interactions between snRNPs may be at work, such that ribonucleoproteins are 
unable to bind efficaciously at a 3’ acceptor site unless snRNPs are also present 
at the downstream splice donor. Consistent with this suggestion is a recent 
model which describes exon definition as an early step required for efficient 
splicing (Robberson et al., 1990). According to this scheme, U1 also functions 
at 3’ splice sites, and it is proposed that this interaction at the 3’ splice site 
dictates sliceosome assembly. The authors suggest that this interaction at the 
3’ splice site includes a mechanism for scanning downstream for an acceptable 
5’ splice donor and that recognition of a suitable donor sequence within 
approximately 300 bases is necessary for efficient spliceosome complex 
formation at the preceding 3’ acceptor site. This step of "exon definition" would 
thus be a necessary element of the splicing pathway, required in order for the 
preceding intron to be excised. If no acceptable 5’ splice site can be found 
within -300 bases of the 3’ splice site, exon definition does not occur, stable 
assembly intermediates do not form, and exon skipping can result. 
It is also of interest that, although the mutation in patient MC alters the 
splice consensus sequence, the mutated sequence still appears to be a 
reasonably good donor. It has been shown that the lower limit of intron size 
allowable for proper splicing to occur is about 65-80 nucleotides (Steitz, 1988; 
Weiringa et al., 1984), and, in fact, the intron separating exon 7 from exon 8 
consists of only 80 bases. This suggests that splicing of exon 7 to exon 8 may 
already be an inefficient process and that, when the splice site at the end of 
exon 7 becomes even slightly less effective, correct splicing may become even 
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more untenable. This argument, however, is not entirely consistent with the 
model of exon definition given above, because stable exon definition should still 
occur to allow splicing of intron 6, irrespective of the efficiency of the 
downstream splicing event. Interactions between snRNPs at neighboring splice 
sites may possibly dictate the most likely splicing pattern to occur. It is hoped 
that a further analysis of mutations such as these will contribute to better 
understanding of the mechanisms by which the spliceosomal machinery 
processes RNA transcripts into mature mRNAs. 
Another question raised by these defects is what effect these mutations 
have at the level of the mature OTC protein. Because the deletions in the 
mRNA are in-frame, it is possible that the products of translation could be at 
least somewhat functional in catalysis. When homogenates from these patients 
were assayed for OTC cross-reacting material, however, none was observed. 
In addition, OTC assays showed no evidence for any OTC activity in these 
patients (data not shown). The step (or steps) in the complex pathway from 
RNA transcript to mature protein responsible for the enzyme deficiency in these 
patients remains to be defined. Export to the cytoplasm of the mRNAs or their 
stability could be affected. The Northern blot data demonstrate that patient MC 
has a reduced, but significant amount of OTC message present, whereas 
patients RD and OW have greatly reduced amounts compared with normal. 
While this suggests that reduced levels of processed mRNA in the cytoplasm 
may be one consequence of these mutations, the fact that one patient had 
nearly normal levels of OTC mRNA yet still produced no OTC cross-reacting 
material, emphasizes the observation that decreased amounts of message 
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cannot fully explain the deficiency observed. It could be that the deletions in the 
protein omit important regions which direct mitochondrial import, mediate trimer 
assembly, or confer stability. In all of these cases, the mutant protein would be 
likely to be rapidly degraded. Further studies may determine more precisely the 
relationship between the mutations described here and the observed enzyme 
deficiency. 
Further study is also necessary to determine the nature of the molecular 
lesions producing disease in the other patients studied. Investigation of other 
single gene disorders such as the thalassemias and hemophilias (Kazazian and 
Boehm, 1988; Youssoufian, etal., 1988; Weatherall, 1987) have demonstrated 
that common types of mutations leading to disease are deletions, single base 
nonsense and missense changes, splicing errors, and frameshift errors. Less 
commonly observed are such changes as alterations in promoter regions affect¬ 
ing transcription, inversions, and insertions. In the four additional patients in 
whom amplifiable cDNAs could be produced, it is likely that small mutations 
such as point mutations or single to several base insertions or deletions 
resulting in frameshifts have occurred. These cDNAs were digested with several 
combinations of restriction endonucleases in an attempt to locate regions 
containing deletions or insertions without success. They were also digested 
with Taq I to determine whether any of these patients had an alteration in a site 
for this enzyme as has been seen in unrelated patients by other workers, but 
none exhibited any alterations in cDNA Taq I sites. Although these mutations 
are most likely small ones, only one of them demonstrated any OTC cross 
reacting material, and, even then, the amount was minimal. In those four 
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patients in whom no amplified cDNAs were produced, it is difficult to determine 
what mechanism of mutation is most likely to account for disease. In two of 
these patients a control amplification with primers for 13-PCC yielded cDNA 
products suggesting that mRNA was present. OTC mRNA may be more 
unstable than 13-PCC message, however, and it may simply be that the liver 
samples used were too degraded for obtaining OTC mRNAs in all four. 
Therefore, another approach may be needed to detect and characterize 
mutations in these patients. 
In summary, we were able to identify 3 cases of aberrant RNA splicing 
out of seven OTC deficient patients from whom we could obtain sufficient 
quantities of cDNA for study using PCR. These are the first cases of human 
OTC deficiency for which aberrantly spliced products have been observed. 
Given the number of these errors found among these patients, it may be that 
abnormal RNA splicing is a common mechanism of disease in OTC deficiency, 
just as many of the thalassemias have been found to be due to errors of RNA 
splicing. To date, only a limited number of inherited diseases have been found 
to be due to splicing errors. The use of techniques which simplify gene 
analysis, such as PCR, may reveal that splicing errors are a more common 
mechanism of mutation than has previously been believed. Better 
understanding of the mechanisms of these diseases will be crucial not only to 
simplify diagnoses, but also to develop strategies for their treatment. 
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Figure 1: 
Structure of OTC genomic DNA and its representation in the OTC cDNA. 
Primers IL and IXaR, which correspond to 5’ and 3’ non-coding sequence, were 
used to amplify a region of the cDNA containing the entire coding sequence of 
the cDNA, producing a 1242 bp product in control samples. The numbers 
below the representation of the cDNA indicate exon lengths in nucleotides. 
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Figure 2: 
Agarose gel electrophoresis of amplified cDNAs from patients exhibiting less 
than full length products. 10 /J aliquots were taken from each 100 /J PCR 
amplification mixture and electrophoresed on 1% agarose. A control OTC cDNA 
template (pH0731) was used for comparison. Left: Lane 1: Patient RD. Lane 
2: pH0731. Lane 3: Hae Ill-digested0X174 size markers. Right: Lane 1: 
Patient OW. Lane 2: Patient MC. Lane 3: pH0731. Lane 4: Hae Ill-digested 
0X174 size markers. 
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Figure 3: 
Agarose gel electrophoresis of a partial amplified cDNA for 8-propionyl CoA 
carboxylase. 50 iA aliquots from each PCR reaction mixture were 
electrophoresed on 1% agarose. Lane 1: Patient DG. Lane 2: Patient BM. 
Lane 3: Patient BC. Lane 4: Patient PF. Lane 5: Control. Lane 6: Size 
markers. 
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Figure 4: 
Agarose gel electrophoresis of restriction endonuclease-digested cDNA from 
patient OW. Aliquots were taken from cDNA PCR reactions, subjected to 
digestion with Acc I and Xho I, and electrophoresed on 3% NuSieve agarose. 
Lane 1: Patient OW. Lane 2: pH0731. Lane 3: Size markers. The arrow 
designates the shortened fragment seen in patient OW. 
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Figure 5: 
Agarose gel electrophoresis of restriction endonculease-digested cDNAs from 
patients RD and MC. Aliquots were taken from PCR reactions, subjected to 
digestion with Asp 718 (Kpn I) and Hae III, and electrophoresed on 3% NuSieve 
agarose. The arrows designate the shortened fragments observed in these 
patients. Left: Lane 1: pH0731. Lane 2: Patient MC. Lane 3: Size markers. 
Right: Lane 1: Size markers. Lane 2: Patient RD. Lane 3: pH0731. The extra 
band of 200 bp seen in lane 2 on the right is a non-specific product carried over 
from the amplification step. 
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Figure 6: 
Agarose gel electrophoresis of restriction endonuclease-digested cDNAs from 
patients RD and MC. Aliquots were taken from PCR reactions, subjected to 
digestion with Msp I and electrophoresed on 3% NuSieve agarose. The arrows 
designated the approximately 1000 base fragment observed in the absence of 
the second Msp I site of the cDNA, which when present yields the 527 and 533 
base fragments shown. Left: Lane 1: Patient RD. Lane 2: pH0731. Lane 3: 
Size markers. Right: Lane 1: Patient MC. Lane 2: pH0731. Lane 3: Size 
markers. 
57 


58 
Figure 7: ~ 
Restriction maps of the normal 1242 base amplified cDNA when subjected to 
digestion with the enzymes shown. Also shown are the normal expected band 
> i 
sizes. 
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Figure 8: 
Sequence of OW cDNA. Amplified cDNA from patient OW was digested with 
Xho I and Sea I, and the fragment between these sites was subcloned into the 
Xho I and Eco ftV sites of pBluescript KS and sequenced using Sequenase. 
The relevant portion of the gel and its interpretation are shown. 
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Figure 9: 
Sequences of MC and RD cDNAs. Amplified cDNA from patients RD and MC 
were digested with Asp 718 and Bst Y\, and fragments between the third Bst VI 
site and the Asp 718 site of the cDNA were subcloned into the Asp 718 and 
Bam H1 sites of pBluescript and sequenced. Left: Sequencing gel of patient 
MC. Right: Sequencing gel from patient RD. Relevant portions of the gels and 
their interpretations are shown. 
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Figure 10: 
Diagram showing the deletions in the cDNAs from these patients, with the 
normal sequences above. 
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Figure 11: 
Sequence of genomic DNA from patient OW. Genomic DNA was amplified as 
described and subcloned into the Sma I site of pBluescript and sequenced. A 
portion of the sequencing gel is shown with its interpretation. The T (arrow) is 
an A in control. 
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Figure 12: 
Sequence of genomic DNA from patient RD. DNA was amplified, subcloned, 
and sequenced as above. The C (arrow) is normally a T. 
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Figure 13: 
Sequence of genomic DNA from patient MC. DNA was amplified, subcloned, 
and sequenced as above. The G (arrow) is normally an A. 
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Figure 14: 
Northern blot of liver RNA probed for OTC, washed, and re-probed with a 
mutase probe as an internal control. Left: Probed for OTC; Lane 1: Normal 
liver. Lane 2: Patient MC. Lane 3: Patient RD. Lane 4: Patient OW. Lane 5 
Patient CC. Lane 6: Patient JF. Lane 7: Patient FN. Lane 8: Patient MT. 
Right: The same filter washed and probed with mutase. 
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Figure 15: 
Western blot of liver extracts analyzed for cross reactive material to anti-OTC 
and anti-methylmalonyl-CoA mutase antisera. The first lane contains a 
homogenate analyzed directly, whereas the other lanes are immunoprecipitated 
material (see Materials and Methods). Lanes 1 and 2: Normal liver. Lane 3: 
Patient MC. Lane 4: Patient RD. Lane 5: Patient OW. Lane 6: Patient CC. 
Lane 7: Patient JF. Lane 8: Patient FN. Lane 9: Patient MT. 
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Figure 16: 
Consensus splice-site sequences changed in these patients compared to wild 
type sequence and scored according to Shapiro and Senepathy (1987). 
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